IDEXX Laboratories : Raymond James 45th Annual Institutional Investors Conference presentation

Safe Harbor Disclaimer

The following presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward- looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. Forward-looking statements contained in the presentation include discussions about growth opportunities for our business and industry, our anticipated total addressable sector opportunity, industry trends, our innovation strategy and plans, expectations regarding product development, product launches and capabilities of new products and services, future premium instrument placement opportunities, expectations and beliefs regarding the resiliency and durability of our business model, business plans and prospects, future operating and financial performance and other future events. No forward-looking statement can be guaranteed. You are cautioned not to put undue reliance on such forward-looking statements, which speak only as of today's date. The Company assumes no obligation, and expressly disclaims any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reports filed by the Company pursuant to United States securities laws contain discussions of the risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements and you should carefully evaluate forward-looking statements together with the many risks, uncertainties and other factors that affect our business, particularly the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Quantitative and Qualitative Disclosures About Market Risks," in our most recent Annual Report on Form 10-K, as well as any subsequent filings on Forms 10-Q and 8-K. You are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at www.sec.govand via the Company's website at www.idexx.com).

We refer in this presentation to our 2024 outlook communicated on February 5, 2024. These references speak only as of the date on which they were communicated and shall not be deemed to be a reiteration or affirmation of the guidance or an indication that our expectations have not changed since that time. We also refer in this presentation to our long-term financial model, including revenue growth potential, long-term EPS growth potential, potential average annual comparable operating margin gain, and potential capital allocation leverage. None of these references constitute and shall not be deemed to be the Company's outlook, guidance or projections.

Non-GAAP Financial Measures

In this presentation, we refer to certain non-GAAP financial measures. While we believe that these non-GAAP financial measures are useful in evaluating our business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. For a reconciliation to the most comparable GAAP financial measures, we refer you to our footnotes and the Appendix to this presentation, which also refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2023, available at www.idexx.com/investors.

Please refer to additional footnotes in the Appendix.

IDEXX's Purpose is Aligned with our Business Strategy

"To be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock."

• Giving pets a voice through advanced diagnostics
• Providing microbiology tests that ensure the safety of drinking water and other water supplies
• Delivering diagnostic tests and services to monitor the health of herd and flock animals worldwide

IDEXX Solutions Deliver Exceptional Customer Value

0

IDEXX CAG Diagnostics Recurring Revenue Growth has Outpaced Practice and Sector Diagnostics Growth

IDEXX U.S. CAG Dx Recurring Revenue Organic Growth and U.S. Revenue Growth per Practice*

(2018 - 2023 CAGR)

3 Non-GAAP financial measure, please refer to Appendix for descriptive footnotes.

* Note that we estimate net new practice formation adds ~1% of incremental sector growth per year beyond per practice growth.

Source: Analysis based on IDEXX Practice Intelligence data n = ~8,250 practices. Clinical revenue is associated with clinical visits, where the reason for visit involves an interaction between a veterinary clinician and a pet, including wellness and non- wellness visit types.

Step-up in Pet Population Drives Sector Volumes Higher

2020 2021 2022 2023

• Based on modeling of dog and cat population growth leveraging analyses of multiple data sources. **Analysis based on IDEXX Practice Intelligence data (n = ~8,500 practices), weighted to be representative of the U.S based on practice size and region.